Pfizer 3Q Revenues: $12.1 billion (-4%) 3Q Earnings: $2.2 billion (-71%) YTD Revenues: $36.0 billion (-8%) YTD Earnings: $9.0 billion (-46%) Comments: Biopharma revenues were $10.2 billion in the quarter, up 3%, primarily driven by the performance of Vyndaqel/Vyndamax, growth from the Biosimilars portfolio, as well as continued strength from key brands including: Eliquis, Ibrance, Xeljanz, Inlyta and Xtandi. Vyndaqel/Vyndamax global revenues were $351 million, up 125% operati...